These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37907716)

  • 21. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
    Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
    Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
    Li ZY; Zhang C; Chen L; Chen BD; Li QZ; Zhang XJ; Li WP
    Phytother Res; 2017 May; 31(5):729-739. PubMed ID: 28240396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
    Zhu D; Tu M; Zeng B; Cai L; Zheng W; Su Z; Yu Z
    Cancer Med; 2017 Feb; 6(2):452-462. PubMed ID: 28064447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
    Prasad G; Sottero T; Yang X; Mueller S; James CD; Weiss WA; Polley MY; Ozawa T; Berger MS; Aftab DT; Prados MD; Haas-Kogan DA
    Neuro Oncol; 2011 Apr; 13(4):384-92. PubMed ID: 21317208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
    Quann K; Gonzales DM; Mercier I; Wang C; Sotgia F; Pestell RG; Lisanti MP; Jasmin JF
    Cell Cycle; 2013 May; 12(10):1510-20. PubMed ID: 23598719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
    Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; Mohile N; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF
    Neuro Oncol; 2015 Sep; 17(9):1275-83. PubMed ID: 26019185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
    Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
    Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
    [No Abstract]   [Full Text] [Related]  

  • 31. Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
    Ye T; Chen R; Zhou Y; Zhang J; Zhang Z; Wei H; Xu Y; Wang Y; Zhang Y
    Bioengineered; 2022 May; 13(5):11646-11655. PubMed ID: 35505656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
    Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
    Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
    Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
    Radoul M; Chaumeil MM; Eriksson P; Wang AS; Phillips JJ; Ronen SM
    Mol Cancer Ther; 2016 May; 15(5):1113-22. PubMed ID: 26883274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair.
    Jiao W; Zhu S; Shao J; Zhang X; Xu Y; Zhang Y; Wang R; Zhong Y; Kong D
    Biomed Res Int; 2022; 2022():8568528. PubMed ID: 35872860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
    Yi GZ; Liu YW; Xiang W; Wang H; Chen ZY; Xie SD; Qi ST
    J Neurol Sci; 2016 Aug; 367():101-6. PubMed ID: 27423571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
    Zhang P; Chen XB; Ding BQ; Liu HL; He T
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.